Proshares Trust (ZBIO) EBIAT (2023 - 2025)
Historic EBIAT for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.
- Zenas BioPharma's EBIAT fell 3339.9% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.9 million, marking a year-over-year decrease of 4723.51%. This contributed to the annual value of -$157.0 million for FY2024, which is 32290.7% down from last year.
- According to the latest figures from Q3 2025, Zenas BioPharma's EBIAT is -$51.5 million, which was down 3339.9% from -$52.2 million recorded in Q2 2025.
- In the past 5 years, Zenas BioPharma's EBIAT registered a high of $35.6 million during Q3 2023, and its lowest value of -$52.6 million during Q4 2024.
- Over the past 3 years, Zenas BioPharma's median EBIAT value was -$38.0 million (recorded in 2024), while the average stood at -$31.5 million.
- Per our database at Business Quant, Zenas BioPharma's EBIAT tumbled by 20841.95% in 2024 and then crashed by 2086.33% in 2025.
- Quarter analysis of 3 years shows Zenas BioPharma's EBIAT stood at -$24.6 million in 2023, then tumbled by 113.93% to -$52.6 million in 2024, then grew by 2.09% to -$51.5 million in 2025.
- Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.